|BITGF -- USA Stock|| |
USD 13.18 0.00 0.00%
Mr. Ove H. Mattsson no longer serves as Chairman of the Board of Directors of Biotage AB effective as of April 26, 2018. He has held the position since April 27, 2007. He was on the Companys Board for fourteen years serving as its Chairman until 2006. Mr. Mattsson is Management Consultant. He also serves as Board Member at Vironova Medical AB and Vironova AB. He is also Member of the Royal Swedish Academy of Engineering Sciences
Age: 77 Chairman Since 2007 Ph.D
46 18 56 59 00 http://www.biotage.com
Mattsson has obtained a Doctorate of Philosophy degree and is Associate Professor in Organic Chemistry.
The company has return on total asset (ROA)
of 9.72 %
which means that it generated profit of $9.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 23.62 %
meaning that it generated $23.62 on every $100 dollars invested by stockholders.
The company has accumulated 12.31 M in total debt with debt to equity ratio (D/E) of 16.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biotage AB has Current Ratio of 2.81 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Biotage AB , a life science company, provides solutions, knowledge, and experience in the areas of analytical chemistry, medicinal chemistry, peptide synthesis, separation, and purification in the United States, Europe, Japan, China, and internationally. It sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions and commercial, hospitalbio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. Biotage AB operates under Medical Instruments Supplies classification in USA and traded on OTC Market. It employs 7 people.Biotage AB (BITGF) is traded on OTC Market in USA. It is located in Box 8 and employs 397 people.
Biotage AB Leadership Team
|Karolina Lawitz, Member of the Board of Directors|
|NilsOlof Bjork, Director|
|Yvonne Martensson, Director|
|Steve Jordan, Chief Scientific Officer|
|Love Amcoff, Director, Employee Representative|
|Anders Wikstrom, Vice President - Operations|
|Thomas Eklund, Member of the Board of Directors|
|Lars Backman, Vice President of Corporate Development|
|Anders Walldov, Member of the Board of Directors|
|Ove Mattsson, Chairman of the Board of Directors|
|Peter Ehrenheim, Member of the Board of Directors|
|Torben Joergensen, President and CEO|
|Paul Belton, Vice President - Business Development|
|Malin Albertsson, Director, Employee Representative|
|Erika Johnson, CFO|
Stock Performance Indicators
Macroaxis portfolio users are unresponsive in their opinion about investing in Biotage AB. What is your opinion about investing in Biotage AB? Are you bullish or bearish?
and pair trading evaluation for Biotage AB and Vedanta Limited
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return